Your browser doesn't support javascript.
loading
The vaccinia-based Sementis Copenhagen Vector coronavirus disease 2019 vaccine induces broad and durable cellular and humoral immune responses.
Eldi, Preethi; Cooper, Tamara H; Prow, Natalie A; Liu, Liang; Heinemann, Gary K; Zhang, Voueleng J; Trinidad, Abigail D; Guzman-Genuino, Ruth Marian; Wulff, Peter; Hobbs, Leanne M; Diener, Kerrilyn R; Hayball, John D.
Afiliação
  • Eldi P; Experimental Therapeutics Laboratory, Clinical and Health Science Unit, University of South Australia, Adelaide, SA, Australia.
  • Cooper TH; Experimental Therapeutics Laboratory, Clinical and Health Science Unit, University of South Australia, Adelaide, SA, Australia.
  • Prow NA; Experimental Therapeutics Laboratory, Clinical and Health Science Unit, University of South Australia, Adelaide, SA, Australia.
  • Liu L; Experimental Therapeutics Laboratory, Clinical and Health Science Unit, University of South Australia, Adelaide, SA, Australia.
  • Heinemann GK; Experimental Therapeutics Laboratory, Clinical and Health Science Unit, University of South Australia, Adelaide, SA, Australia.
  • Zhang VJ; Experimental Therapeutics Laboratory, Clinical and Health Science Unit, University of South Australia, Adelaide, SA, Australia.
  • Trinidad AD; Experimental Therapeutics Laboratory, Clinical and Health Science Unit, University of South Australia, Adelaide, SA, Australia.
  • Guzman-Genuino RM; Sementis Limited, Hackney, SA, Australia.
  • Wulff P; Sementis Limited, Hackney, SA, Australia.
  • Hobbs LM; Experimental Therapeutics Laboratory, Clinical and Health Science Unit, University of South Australia, Adelaide, SA, Australia.
  • Diener KR; Sementis Limited, Hackney, SA, Australia.
  • Hayball JD; Experimental Therapeutics Laboratory, Clinical and Health Science Unit, University of South Australia, Adelaide, SA, Australia.
Immunol Cell Biol ; 100(4): 250-266, 2022 04.
Article em En | MEDLINE | ID: mdl-35188985
ABSTRACT
The ongoing coronavirus disease 2019 (COVID-19) pandemic perpetuated by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has highlighted the continued need for broadly protective vaccines that elicit robust and durable protection. Here, the vaccinia virus-based, replication-defective Sementis Copenhagen Vector (SCV) was used to develop a first-generation COVID-19 vaccine encoding the spike glycoprotein (SCV-S). Vaccination of mice rapidly induced polyfunctional CD8 T cells with cytotoxic activity and robust type 1 T helper-biased, spike-specific antibodies, which are significantly increased following a second vaccination, and contained neutralizing activity against the alpha and beta variants of concern. Longitudinal studies indicated that neutralizing antibody activity was maintained up to 9 months after vaccination in both young and middle-aged mice, with durable immune memory evident even in the presence of pre-existing vector immunity. Therefore, SCV-S vaccination has a positive immunogenicity profile, with potential to expand protection generated by current vaccines in a heterologous boost format and presents a solid basis for second-generation SCV-based COVID-19 vaccine candidates incorporating additional SARS-CoV-2 immunogens.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 / 4_TD Base de dados: MEDLINE Assunto principal: Vacínia / COVID-19 Tipo de estudo: Observational_studies Limite: Animals / Humans Idioma: En Revista: Immunol Cell Biol Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 / 4_TD Base de dados: MEDLINE Assunto principal: Vacínia / COVID-19 Tipo de estudo: Observational_studies Limite: Animals / Humans Idioma: En Revista: Immunol Cell Biol Ano de publicação: 2022 Tipo de documento: Article